Key points are not available for this paper at this time.
C3G is characterized by C3 deposition in the glomeruli caused by abnormal activation of the alternative complement pathway. There are no approved therapies for C3G. Despite supportive care, C3G remains a progressive form of kidney disease, with novel treatments needed to improve outcomes. Contemporary datasets on the clinical burden of patients with C3G are limited. Using real-world evidence from electronic medical records, this study describes the characteristics of patients diagnosed with C3G in the US.
Ndife et al. (Mon,) studied this question.